Single GLP-1 agonism (the semaglutide model) drives appetite suppression and glucose control but plateaus in how much weight it can shift
This schedule, documented across SURPASS clinical trials, starts at the lowest therapeutic dose and increases by 2.5 mg every four weeks
Individuals who adhere to a diet where B12 intake may be limited, are also good candidates, as well as individuals with conditions that affect B12 absorption
Ongoing Commitment: Optimal results typically require ongoing treatment, though protocols may be adjusted over time based on progress and goals
We review your health history, current medications, and recovery or wellness goals
Understanding general peptide response timelines contextualizes expectations across different applications